Jazz acquiring Celator for $1.5B

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is to acquire Celator Pharmaceuticals Inc. (NASDAQ:CPXX) for $30.25 per share, or about $1.5 billion in cash. The price is a 73% premium on its Friday close of $17.53, and a 1,701% premium on its March 14 close of $1.68, before Celator disclosed positive data for Vyxeos ( CPX-351) to treat acute myelogenous leukemia (AML).

Celator jumped $12.55 (72%) to $30.08 on Tuesday's news. ...